A survey of cancer morbidity and mortality in vaccinees seven to 12 years after the administration of live vaccine propagated in human diploid cells.
Using record linkage, cancer morbidity and mortality were examined in 2973 recipients of RA 27/3 strain rubella vaccine propagated in WI 38 cells. During the follow-up reported (mean duration 9.8 years; range seven to 12 years) the rate of cancer notifications and of deaths from cancer were similar to those observed in the equivalent age range of the general population.
D000293:Adolescent; D000367:Age Factors; D002460:Cell Line; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009369:Neoplasms / Q000401:mortality*; D009374:Neoplasms, Experimental; D012411:Rubella Vaccine / Q000009:adverse effects*
D012411:Rubella Vaccine